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Lung cancer is the leading cause of cancer-related
deaths in men and women worldwide and has a 
very poor prognosis [1]. There are two major types of
lung cancer: small cell lung carcinoma (SCLC) and
non-small cell lung carcinoma (NSCLC). Large cell
carcinoma has the worst prognosis of all NSCLCs
[2,3]. Chemotherapy has many intolerable side effects
and reached a therapeutic plateau for treating lung
cancer [1]. It is essential to find novel agents with potent
anti-cancer activity and few side effects. According to
epidemiological data, there is an inverse relationship
between the frequency of vegetable consumption and
lung cancer [4–7]. Many natural food compounds have
been demonstrated to exert a protective effect against
lung cancer, including lycopene [8] and selected veg-
etables [9,10] but, to date, no specific type of vegetable
seems to be particularly efficacious.
Toona sinensis Roem is a widely distributed native
plant of South-East Asia. The leaves and young shoots
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Toona sinensis extracts have been shown to exhibit anti-cancer effects in human ovarian cancer cell
lines, human promyelocytic leukemia cells and human lung adenocarcinoma. Its safety has also
been confirmed in animal studies. However, its anti-cancer properties in human lung large cell
carcinoma have not been studied. Here, we used a powder obtained by freeze-drying the super-
natant of centrifuged crude extract from Toona sinensis leaves (TSL-1) to treat the human lung car-
cinoma cell line H661. Cell viability was evaluated by the 3-(4-,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide assay. Flow cytometry analysis revealed that TSL-1 blocked H661 cell cycle
progression. Western blot analysis showed decreased expression of cell cycle proteins that pro-
mote cell cycle progression, including cyclin-dependent kinase 4 and cyclin D1, and increased
the expression of proteins that inhibit cell cycle progression, including p27. Furthermore, flow
cytometry analysis showed that TSL-1 induced H661 cell apoptosis. Western blot analysis
showed that TSL-1 reduced the expression of the anti-apoptotic protein B-cell lymphoma 2, and
degraded the DNA repair protein, poly(ADP-ribose) polymerase. TSL-1 shows potential as a
novel therapeutic agent or for use as an adjuvant for treating human lung large cell carcinoma.
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of Toona sinensis Roem have long been used as an edible
vegetable in China and Malaysia [11]. In traditional
medicine, it is used to treat many diseases such as en-
teritis, dysentery, itchiness, abdomen tumor, diabetes
and hypertension [11–14]. However, few studies have
been done to evaluate its anti-cancer properties. Crude
water extracts from Toona sinensis leaves (TSL-CE) in-
hibit cell proliferation and induce apoptosis of human
lung adenocarcinoma (A549) cells [12]. TSL-1, a pow-
der obtained by freeze-drying the supernatant of cen-
trifuged TSL-CE, has powerful antioxidant activity
and can also inhibit proliferation and induce apopto-
sis of human promyelocytic leukemia cells [15,16].
TSL-2, a powder obtained by freeze-drying the super-
natant of the centrifuged extract of TSL-1 in 99.5%
ethanol, was shown to induce apoptosis of human
ovarian cancer cells and inhibit tumor growth in a
murine xenograft model [14]. Moreover, TSL-1 was
shown to be safe in mice at a highest tested dose of
5 mg/g body weight [17].
Different cancer cell lines with different genetic
characteristics may show different responses to the
same compound, even when they originate from the
same organ [14,18–20]. For example, tea polyphenols
were shown to be more effective on the human lung
carcinoma cell line H661 than on the human lung
adenocarcinoma cell line H441 [20]. In the era of tar-
geted therapy, targeting specific tumors with specific
drugs is expected to produce the greatest effects with
the least side effects. Of the three types of NSCLC cell
lines tested, we found that TSL-1 was most effective
on H661 cells. Further study revealed that TSL-1 can
arrest cell cycle progression, inhibit proliferation and
induce apoptosis of H661 cells.
MATERIALS AND METHODS
Preparation of extracts of Toona sinensis
Roem and other chemicals
Toona sinensis leaves were obtained from Toona sinen-
sis Roem grown in Tuku (Yunlin County, Taiwan) and
were picked and washed thoroughly with water. TSL-
CE was prepared by immersing 1 kg of fresh Toona
sinensis in 1 L of water, and boiling them until 100 mL
of fluid remained, as previously described [12]. The
TSL-CE was then centrifuged at 3,000 rpm for 12 min-
utes and the supernatant was lyophilized by freeze-
drying to obtain a powder, which we called TSL-1.
Cell culture
Human lung adenocarcinoma cell line H441, human
lung squamous cell carcinoma cell line H520, and
human lung large cell carcinoma cell line H661 were
purchased from the Institute of Food Science (Hsinchu,
Taiwan). These cells were cultured in RPMI-1640 me-
dium (Gibco, Invitrogen Corporation, Carlsbad, CA,
USA), supplemented with 10% FBS, 1% penicillin-
streptomycin, 2mM L-glutamine, 10mM HEPES buffer
solution and 1 mM MEM sodium pyruvate solution,
and incubated in a 5% CO2 incubator at 37°C.
Colorimetric assay for cytotoxicity test
Colorimetric assay using 3-(4-,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT; Sigma, 
St Louis, MO, USA) was used to determine cell pro-
liferation and viability [21]. Cells were treated with
different concentrations of TSL-1 (0, 0.125, 0.25, 0.50,
or l mg/mL) for 24 or 48 hours, and untreated cells
were prepared as a control group. After treatment, the
media were replaced with MTT reagent (2 mg/mL
and the cells were incubated in a 5% CO2 incubator at
37°C for 1.5 hours. The media were then aspirated
and dimethyl sulfoxide was added to each well. After
shaking the plates for 5 minutes, light absorbance
values were determined at the wavelength of 540 nm
using a microplate reader to calculate the 50% inhib-
itory concentration (IC50), i.e. the drug concentration
at which the light absorbance value of the experi-
mental group is 50% of that of the control group.
Western blot analysis
Cells were treated with 0.5 mg/mL or 1 mg/mL TSL-1
for 24 hours, washed twice with ice-cold phosphate-
buffered saline (PBS) and then harvested in a lysis
buffer (50 mM Tris-base, 150 mM NaCl, 5 mM EDTA,
50 mM NaF, 0.1 mM sodium orthovanadate, pH 7.4,
and 1% Triton X-100 in 5 mL) containing protease
inhibitors (1 M PMSF, 1 mg/mL leupeptin, 100 mM
benzidine, 2 μL/mL aprotinin, and 2 mg/mL pep-
statin A) for 10 minutes at 4°C. The cell lysates were
centrifuged at 12,000 rpm for 10 minutes. Total pro-
tein content was determined using the protein assay
dye reagent concentrate (Bio-Rad, Hercules, CA,
USA), with bovine serum albumin as a standard. The
protein extracts were subjected to a 12% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis and
transferred to the PVDF membranes, and the blots
were blocked in 5% non-fat milk at 37°C for 1 hour.
The blots were then probed with anti-actin antibody
(Chemicon, Temecula, CA, USA); anti-cyclin D1, cyclin-
dependent kinases (CDK)-4 and p27 antibodies (Santa
Cruz, CA, USA); anti-Bcl2 antibody (Cell Signaling,
Beverly, MA, USA) and anti-poly(ADP-ribose) poly-
merase (PARP) antibody(Zymed, San Francisco, CA,
USA) for 1 hour at room temperature. After washing
in 1× tris-buffered saline/Tween buffer, blots were
incubated for 1 hour with the appropriate secondary
antibody. The membranes were developed using an
enhanced chemiluminescence system (Amersham
International, UK) and exposed to high sensitivity film.
The images were analyzed by computer-assisted den-
sitometry and Bio-1D V.97 software (Vilber Lourmat,
France).
Determination of cell cycle by flow
cytometry
Cells were treated with TSL-1 for 24 hours. After wash-
ing with PBS, the cells were detached from the culture
dish using trypsin/EDTA and fixed with 70% alcohol
at 4°C. The samples were then incubated with 10 μg/
mL RNase A and 50 μg/mL propidium iodide (PI) for
30 minutes at 37°C. DNAcontent and cell cycle progres-
sion was studied by flow cytometry and results were
analyzed using Multi-Cycle DNA analysis software.
Measurement of cell apoptosis by flow
cytometry
Annexin-V staining was performed to detect apop-
totic cells. After treating with TSL-1, cells were washed
with HEPES buffer (pH 7.4, 10 mM Hepes/NaOH,
140 mM NaCl, 5 mM CaCl2) and centrifuged at 1,200
rpm for 5 minutes at 4°C. The cell pellets were resus-
pended in 100 μL of staining solution (2μL of Annexin-V
fluorescein labeling reagent, and 2 μL of 0.5 mg/mL
PI in 100 μL of Hepes buffer) and incubated for 15 min-
utes at room temperature in the dark. Samples were
centrifuged again at 1,200 rpm for 5 minutes at 4°C
and the cells were filtered through a 30 μm mesh to in-
dividual cell. Necrotic cells were double-stained with
Annexin-V and PI, while apoptotic cells were only
stained with Annexin-V. The relative fluorescent 
intensities of Annexin-V and PI were analyzed by
flow cytometry with WINDI 2.5 software.
Statistical analysis
All studies were done with six duplicates. Results are
presented as mean ± standard deviation. One-tailed
Student’s t test was used to analyze the difference be-
tween two groups. Significance was defined as p<0.05
for all tests.
RESULTS
Effects of TSL-1 on cell survival of 
H661 cells
Cells were exposed to 0, 0.125, 0.25, 0.5, or 1 mg/mL
TSL-1 for 24 or 48 hours. TSL-1 induced cell death 
in a dose- and time-dependent manner in all three
human lung carcinoma cell lines (H441, H520 and
H661), as determined by the MTT assay. The IC50
of TSL-1 at 24 hours was 1.2 mg/mL, 0.73 mg/mL
and 0.29 mg/mL for H441, H520 and H661 cells,
respectively. H661 was then selected for further stud-
ies because H661 is derived from a human lung large
cell carcinoma, which has the worst prognosis of all
NSCLC types. Moreover, TSL-1 showed the most 
potent inhibitory activity against H661 IC50 values of
0.29 mg/mL at 24 hours and 0.12 mg/mL at 48 hours
(Figure 1).
Effects of TSL-1 on cell cycle progression
and cell cycle protein expression
H661 cells were incubated with 0.5 mg/mL TSL-1 for
24 hours and flow cytometry was used to analyze 
cell cycle progression. We found that TSL-1 effec-
tively arrested the cell cycle at the G1 phase (Figure 2).
TSL-1 also significantly decreased the expression of
cyclin D1 and CDK4 in a dose-dependent manner,
when compared with the control group. Conversely,
TSL-1 significantly increased the expression of p27 
in a dose-dependent manner when compared with
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Figure 1. Effect of TSL-1 on cell survival of H661 cells. TSL-1
induced cell death in a dose- and time-dependent manner. *p<0.05
versus control; †p < 0.01 versus control. TSL-1 = the supernatant
of centrifuged crude extract from Toona sinensis leaves.
the control group (p < 0.05) (Figure 3). These data sug-
gest that TSL-1 caused cell cycle arrest in H661 cells
in association with decreased expression of proteins
that promote cell cycle progression (cyclin D1 and
CDK4) and increased expression of the cell cycle
inhibitory protein p27.
Effects of TSL-1 on apoptosis of H661 cells
H661 cells were incubated in RPMI 1640 medium with
or without 0.5 mg/mL TSL-1 for 24 hours after which
apoptosis was determined based on Annexin-V and
PI staining. The proportion of cells that had undergone
apoptosis was significantly greater compared with
cells in the control group (p < 0.01) (Figure 4).
Effect of TSL-1 on apoptosis-related
proteins
To clarify the mechanisms by which TSL-1 induced
apoptosis of H661 cells, H661 cells were incubated 
in 0.5 mg/mL or 1 mg/mL TSL-1 for 24 hours, and
the proteins were extracted for Western blotting. We
found that TSL-1 reduced the expression of Bcl2 in a
concentration-dependent manner (Figure 5). It is well
known that Bcl2 is a potent anti-apoptotic protein that
is expressed in lung cancer [22,23]. We also found
that TSL-1 promotes the cleavage of PARP (Figure 5).
It is also well known that PARP cleavage is vital for
appropriate apoptosis activity [24]. Thus, TSL-1 may
induce H661 cell apoptosis through pathways involv-
ing Bcl2 and PARP.
DISCUSSION
Cell cycle progression in mammalian cells is con-
trolled by positive regulators such as cyclins and
CDK, and by negative regulators such as CDK in-
hibitors. Cyclin D1 is over-expressed in almost 60%
of resectable NSCLCs [25]. The over-expression of
cyclin D1 is associated with lymph node metastasis
[26] and is a predictor of shorter survival time of 
patients with NSCLC [27,28]. By contrast, the absence
of cyclin D1 expression may have a favorable prog-
nostic value [29]. CDK inhibitors, which can block
the cell cycle, have been proposed as tumor suppres-
sor genes [30]. The p27 gene, one such CDK inhibitor,
is also a prognostic factor that is positively associated
with the overall survival time of patients with NSCLC
[31,32]. In our study, TSL-1 reduced the expression of
cyclin D1, increased the expression of p27 and arrested
cell cycle progression. Thus, TSL-1 may be beneficial
for treating human lung large cell carcinoma.
Apoptosis, programmed cell death, is a physio-
logical process of cell suicide and plays an important
role in the maintenance of tissue homeostasis. DNA
damage and cellular injury caused by drugs or other
mechanisms initiate signaling pathways leading to
apoptosis [33]. Inhibition of apoptosis is one of the
main characteristics of cancer. Defects in apoptosis are
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Figure 2. Effects of TSL-1 on cell cycle progression of H661 cells.
Compared with the control group, TSL-1 significantly arrested
the cell cycle of H661 cells in the G1 phase. *p < 0.05 versus con-
trol cells. TSL-1 = the supernatant of centrifuged crude extract
from Toona sinensis leaves.
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Figure 3. Effect of TSL-1 on cyclin D1, cyclin-dependent kinase 4
and p27 protein expression. TSL-1 significantly reduced the 
protein expression of (A) cyclin D1 and (B) cyclin-dependent
kinase 4, and (C) increased the expression of p27 in a concentra-
tion-dependent manner. Actin was used as an loading control.
TSL-1 = the supernatant of centrifuged crude extract from Toona
sinensis leaves.
implicated in tumorigenesis and drug resistance, and
these defects are also responsible for chemotherapy
failure [34]. Bcl2 is a potent anti-apoptotic protein
that is expressed in SCLC and NSCLC cells [35–38].
Bcl2 over-expression is related to resistance to anti-
cancer agents [22]. PARP is an abundant nuclear en-
zyme that mediates the repair of DNA breaks and is
activated in response to DNA damage induced by ion-
izing radiation, oxidative stress and DNA-binding
anti-cancer drugs [39,40]. PARP activation can rescue
tumor cells from therapeutic DNA damage induced
by chemotherapy agents [24]. In our study, TSL-1
induced cancer cell apoptosis, which was associated
with reduced expression of Bcl2 and degradation of
PARP. Thus, TSL-1 could be used to support the
effects of standard chemotherapy and overcome drug
resistance of cancer cells.
H661 cells are derived from human lung large 
cell carcinoma, which has the worst prognosis of all
NSCLCs. When compared with other NSCLC cell
lines, H661 cells are more resistant to several standard
chemotherapy drugs [41]. Interestingly, the H661 cells
were found to be the most vulnerable cell line to TSL-1
in this study. In another study, tea polyphenols also
showed better effectiveness in H661 cells than in
H441 cells [20]. By contrast, solamargine showed bet-
ter effectiveness in H441 cells than in H661 cells [18].
Therefore, the so-called “drug resistance” is not the real
cause for treatment failure, it only means that we have
not found the most appropriate drug for the cancer
being treated. The reasons for the differences in re-
sponse of these cells lines may involve the distinct
genetic characteristics of the different cancer cell lines.
For example, it is known that H441 has a mutation in
exon 5, codon 158 of p53 [42], while H520 and H661
express non-functional p53 [43], H441 and H520 do
not express p16, and H661 produces a smaller p16
protein [44,45]. However, the underlying mechanisms
still remain unknown. In actual clinical practice, all
three types of NSCLC are treated with similar combi-
nations of standard chemotherapy drugs, so it is little
wonder that the prognosis is poor. In the era of targeted
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Figure 4. Effect of the supernatant of centrifuged crude extract from Toona sinensis leaves on apoptosis of H661 cells. Quadrant 1
(lower left) represents necrotic cells, with double-staining for Annexin-V and PI. Quadrant 4 (upper right) represents apoptotic cells
stained with Annexin-V. Results showed that TSL-1 significantly induced apoptosis compared with the control group (n = 6, *p < 0.01
versus control cells).
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Figure 5. Effects of TSL-1 on Bcl2 expression and PARP cleav-
age. Expression of Bcl2 protein was significantly reduced in a
dose-dependent manner by TSL-1. PARP was degraded into two
components (116 kDa and 85 kDa) after treatment with both doses
of TSL-1 for 24 hours. Actin was used as an loading control.
therapy and tailored therapy, it is now feasible to
conduct further studies to evaluate the effect of TSL-1
specific to human lung large cell carcinoma.
In conclusion, we found that TSL-1 had effects on
cell cycle regulation and apoptosis. In terms of cell
cycle regulation, TSL-1 arrested the cell cycle in the
G1 phase by inhibiting the expression of cyclin D1 and
CDK4 and by increasing the expression of the CDK
inhibitor p27. With respect to apoptosis, TSL-1 pro-
moted apoptotic cell death by decreasing the expres-
sion of Bcl2 and enhancing the cleavage of PARP.
Therefore, TSL-1 may hold some potential as a novel
therapeutic agent or could be used as an adjuvant in
combination with traditional chemotherapy to treat
human lung carcinoma.
ACKNOWLEDGMENTS
The authors are grateful to the Kaohsiung Medical
University, Kaohsiung, Taiwan, and Changhua
Christian Hospital, Changhua, Taiwan, for grant 
support.
REFERENCES
1. Carney DN. Lung cancer—time to move on from
chemotherapy. N Engl J Med 2002;346:126–8.
2. García-Yuste M, Matilla JM, González-Aragoneses F.
Neuroendocrine tumors of the lung. Curr Opin Oncol
2008;20:148–54.
3. Zacharias J, Nicholson AG, Ladas GP, et al. Large cell
neuroendocrine carcinoma and large cell carcinomas
with neuroendocrine morphology of the lung: progno-
sis after complete resection and systematic nodal dis-
section. Ann Thorac Surg 2003;75:348–52.
4. Rylander R, Axelsson G. Lung cancer risks in relation
to vegetable and fruit consumption and smoking.
Int J Cancer 2006;118:739–43.
5. Voorrips LE, Goldbohm RA, Verhoeven DT, et al.
Vegetable and fruit consumption and lung cancer risk
in the Netherlands Cohort Study on Diet and Cancer.
Cancer Causes Control 2000;11:101–15.
6. Sankaranarayanan R, Varghese C, Duffy SW, et al. 
A case-control study of diet and lung cancer in Kerala,
South India. Int J Cancer 1994;58:644–9.
7. Nyberg F, Agrenius V, Svartengren K, et al. Dietary 
factors and risk of lung cancer in never-smokers.
Int J Cancer 1998;78:430–6.
8. Arab L, Steck-Scott S, Fleishauer AT. Lycopene and the
lung. Exp Biol Med 2002;227:894–9.
9. Sun AS, Ostadal O, Ryznar V, et al. Phase I/II study 
of stage III and IV non-small cell lung cancer patients
taking a specific dietary supplement. Nutr Cancer 1999;
34:62–9.
10. Sun AS, Yeh HC, Wang LH, et al. Pilot study of a spe-
cific dietary supplement in tumor-bearing mice and in
stage IIIB and IV non-small cell lung cancer patients.
Nutr Cancer 2001;39:85–95.
11. Edmonds JM, Staniforth M. Toona sinensis. Curtis’ Bot
Mag 1998;15:186–93.
12. Chang HC, Hung WC, Huang MS, et al. Extract from
the leaves of Toona sinensis roemor exerts potent anti-
proliferative effect on human lung cancer cells. Am J
Chin Med 2002;30:307–14.
13. Fan S, Chen HN, Wang CJ, et al. Toona sinensis Roem
(Meliaceae) leaf extract alleviates liver fibrosis via reduc-
ing TGFbeta1 and collagen. Food Chem Toxicol 2007;45:
2228–36.
14. Chang HL, Hsu HK, Su JH, et al. The fractionated
Toona sinensis leaf extract induces apoptosis of human
ovarian cancer cells and inhibits tumor growth in a mu-
rine xenograft model. Gynecol Oncol 2006;102:309–14.
15. Yang HL, Chang WH, Chia YC, et al. Toona sinensis
extracts induces apoptosis via reactive oxygen species
in human promyelocytic leukemia cells. Food Chem
Toxicol 2006;44:1978–88.
16. Hseu YC, Chang WH, Chen CS, et al. Antioxidant activ-
ities of Toona sinensis leaves extracts using different
antioxidant models. Food Chem Toxicol 2008;46:105–14.
17. Liao JW, Chung YC, Yeh JY, et al. Safety evaluation of
water extracts of Toona sinensis Roemor leaf. Food Chem
Toxicol 2007;45:1393–9.
18. Liu LF, Liang CH, Shiu LY, et al. Action of solamargine
on human lung cancer cells: enhancement of the sus-
ceptibility of cancer cells to TNFs. FEBS Lett 2004;577:
67–74.
19. Liang CH, Shiu LY, Chang LC, et al. Solamargine
enhances Her2 expression and increases the suscepti-
bility of human lung cancer H661 and H69 cells to
trastuzumab and epirubicin. Chem Res Toxicol 2007;21:
393–9.
20. Yang GY, Liao J, Kim K, et al. Inhibition of growth and
induction of apoptosis in human cancer cell lines by
tea polyphenols. Carcinogenesis 1998;19:611–6.
21. Scudiero DA, Shoemaker RH, Paull KD, et al.
Evaluation of a soluble tetrazolium/formazan assay
for cell growth and drug sensitivity in culture using
human and other tumor cell lines. Cancer Res 1988;48:
4827–33.
22. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of
lung cancer cells caused by some anti-cancer agents
(MMC, CPT-11, ADM) is inhibited by BCL2. Biochem
Biophys Res Commun 1993;192:30–6.
23. Sun SY, Yue P, Zhou JY, et al. Overexpression of BCL2
blocks TNF-related apoptosis-inducing ligand (TRAIL)-
induced apoptosis in human lung cancer cells. Biochem
Biophys Res Commun 2001;280:788–97.
Anticancer properties of Toona sinensis
Kaohsiung J Med Sci February 2010 • Vol 26 • No 2 73
Kaohsiung J Med Sci February 2010 • Vol 26 • No 274
C.Y. Wang, K.H. Lin, C.J. Yang, et al
24. Nguewa PA, Fuertes MA, Alonso C, et al. Phar-
macological modulation of poly(ADP-ribose) poly-
merase-mediated cell death: exploitation in cancer
chemotherapy. Mol Pharmacol 2003;64:1007–14.
25. Ratschiller D, Heighway J, Gugger M, et al. Cyclin D1
overexpression in bronchial epithelia of patients with
lung cancer is associated with smoking and predicts
survival. J Clin Oncol 2003;21:2085–93.
26. Wang J, Miao LJ, Wu YM, et al. Expression of AKT2,
cyclin D1, and MMP-9 and their correlations to clinico-
pathologic features of non-small cell lung cancer. Chin
J Cancer 2006;25:69–72.
27. Keum JS, Kong G, Yang SC, et al. Cyclin D1 over-
expression is an indicator of poor prognosis in resect-
able non-small cell lung cancer. Br J Cancer 1999;81:
127–32.
28. Caputi M, Groeger AM, Esposito V, et al. Prognostic
role of cyclin D1 in lung cancer. Relationship to prolif-
erating cell nuclear antigen. Am J Respir Cell Mol Biol
1999;20:746–50.
29. Nguyen VN, Mirejovsky P, Mirejovsky T, et al. Expres-
sion of cyclin D1, Ki-67 and PCNA in non-small cell
lung cancer: prognostic significance and comparison
with p53 and BCL2. Acta Histochem 2000;102:323–38.
30. Kawamata N, Miller CW, Koeffler HP. Molecular analy-
sis of a family of cyclin-dependent kinase inhibitor genes
(p15/MTS2/INK4b and p18/INK4c) in non-small cell
lung cancers. Mol Carcinog 1995;14:263–8.
31. Esposito V, Baldi A, De Luca A, et al. Prognostic role of
the cyclin-dependent kinase inhibitor p27 in non-small
cell lung cancer. Cancer Res 1997;57:3381–5.
32. Ishihara S, Minato K, Hoshino H, et al. The cyclin-
dependent kinase inhibitor p27 as a prognostic factor
in advanced non-small cell lung cancer: its immuno-
histochemical evaluation using biopsy specimens. Lung
Cancer 1999;26:187–94.
33. Zhou BS, Elledge SJ. The DNA damage response: put-
ting checkpoints in perspective. Nature 2000;408:433–9.
34. Shivapurkar N, Reddy J, Chaudhary PM, et al.
Apoptosis and lung cancer: a review. J Cell Biochem
2003;88:885–98.
35. Jiang SX, Sato Y, Kuwao S, et al. Expression of BCL2
oncogene protein is prevalent in small cell lung carci-
nomas. J Pathol 1995;177:135–8.
36. Kitagawa Y, Wong F, Lo P, et al. Overexpression of
BCL2 and mutations in p53 and K-ras in resected
human non-small cell lung cancers. Am J Respir Cell
Mol Biol 1996;15:45–54.
37. Walker C, Robertson L, Myskow M, et al. Expression of
the BCL2 protein in normal and dysplastic bronchial
epithelium and in lung carcinomas. Br J Cancer 1995;72:
164–9.
38. Pezzella F, Turley H, Kuzu I, et al. BCL2 Protein in 
non-small-cell lung carcinoma. N Engl J Med 1993;329:
690–4.
39. Lindahl T, Satoh MS, Poirier GG, et al. Post-translational
modification of poly(ADP-ribose) polymerase induced
by DNA strand breaks. Trends Biochem Sci 1995;20:
405–11.
40. D’Amours D, Desnoyers S, D’Silva I, et al. Poly(ADP-
ribosyl)ation reactions in the regulation of nuclear
functions. Biochem J 1999;342:249–68.
41. Paterson J, Uriel C, Egron MJ, et al. Antiproliferative
and apoptotic activities of ketonucleosides and keto-
c-glycosides against non-small-cell lung cancer cells
with intrinsic drug resistance. Antimicrob Agents
Chemother 1998;42:779–84.
42. Khan QA, Anderson LM. Hydrocarbon carcinogens
evade cellular defense mechanism of G1 arrest in non-
transformed and malignant lung cell lines. Toxicol Appl
Pharmacol 2001;173:105–13.
43. Stuschke M, Sak A, Wurm R, et al. Radiation-induced
apoptosis in human non-small-cell lung cancer cell
lines is secondary to cell-cycle progression beyond the
G2-phase checkpoint. Int J Radiat Biol 2002;78:807–19.
44. Shapiro GI, Park JE, Edwards CD, et al. Multiple mech-
anisms of p16INK4A inactivation in non-small cell
lung cancer cell lines. Cancer Res 1995;55:6200–9.
45. Lee JH, Lee CT, Yoo CG, et al. The inhibitory effect of
adenovirus-mediated p16INK4a gene transfer on the
proliferation of lung cancer cell line. Anticancer Res
1998;18:3257–61.
Kaohsiung J Med Sci February 2010 · Vol 26 · No 2 75
收文日期：98 年 4 月 21 日
接受刊載：98 年 10 月 1 日
通訊作者：黃明賢教授
高雄醫學大學附設醫院內科部
高雄醫學大學醫學院醫學系內科學
高雄市十全一路 100 號
香椿萃取液可造成人類大細胞肺癌細胞株
H661 細胞週期休止及凋亡
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香椿萃取物已被證實在人類卵巢癌細胞株、人類白血病細胞株及人類肺腺癌細胞株
A549具有抗癌作用。其安全性也已在動物實驗證實。但香椿萃取物在人類大細胞肺
癌的效果尚未被研究。我們將香椿葉水萃物離心後之上清液加以冷涷乾燥，製成香椿
葉水萃物第一區分（TSL-1），試驗其使用在人類大細胞肺癌細胞株 H661的效果。
細胞存活以MTT assay加以分析。對細胞週期的影響以流式細胞儀加以分析，並以
西方墨點法偵測細胞週期蛋白。我們發現 TSL-1可以阻斷 H661細胞週期的進行，下
降促細胞週期進行的蛋白質，CDK4及 cyclin D1 的表現，增加抑制細胞週期進行的
蛋白質 p27的表現。再者，TSL-1可誘發 H661細胞株的凋亡，下降抗凋亡蛋白 Bcl-
2 的表現，並促進 DNA修復蛋白 PARP的分解。TSL-1可以經由阻斷細胞週期的進
行及促進細胞凋亡來抑制人類大細胞肺癌細胞株 H661，加以無明顯毒性，顯示其有
潛力發展成治療人類大細胞肺癌的輔助藥物。
關鍵詞：凋亡，細胞週期，大細胞肺癌，香椿
（高雄醫誌 2010;26:68–75）
